Expanded Access to Voxelotor for Patients With Sickle Cell Disease Who Have No Alternative Treatment Options
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03943615|
Expanded Access Status : Approved for marketing
First Posted : May 9, 2019
Last Update Posted : December 19, 2019
- Study Details
- Tabular View
- How to Read a Study Record
|Condition or disease||Intervention/treatment|
|Sickle Cell Disease||Drug: Voxelotor|
The purpose of this program is to provide early access to voxelotor for patients with sickle cell disease who have exhausted alternative treatment options and are ineligible for actively-recruiting clinical trials of voxelotor.
This EAP may continue until such time that voxelotor is commercially available or the Sponsor discontinues the voxelotor EAP. Discontinuation may occur earlier if an individual participant or physician or Sponsor Medical Monitor decides to discontinue treatment.
|Study Type :||Expanded Access|
|Expanded Access Type :||Individual Patients|
|See clinical trials of the intervention/treatment in this expanded access record.|
|Official Title:||An Open-Label, Expanded Access Protocol for Patient With Sickle Cell Disease Who Have No Alternative Treatment Options|
- Drug: Voxelotor
Other Name: GBT440
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||12 Years and older (Child, Adult, Older Adult)|
|Sexes Eligible for Study:||All|
- Documented diagnosis of sickle cell disease of any genotype confirmed by laboratory testing during screening
- Ineligible or unable to participate in actively recruiting clinical studies of voxelotor
- Hemoglobin (Hb) ≤ 10.5 g/dL during screening
- No alternative treatment options in the judgment of the treating investigator
- Participants, who if female and of child bearing potential, agree to use highly effective methods of contraception from study start to 30 days after the last dose of voxelotor, and who if male, agree to use barrier methods of contraception from study start to 30 days after the last dose of voxelotor
- Patient has provided documented informed consent (the informed consent form [ICF] must be reviewed and signed by each participant),or for participants under 18 years of age, signed parental/legal guardian consent and participant assent.
- Female who is breast feeding or pregnant
- Hepatic dysfunction characterized by alanine aminotransferase (ALT) >4 × ULN
Patients with clinically significant bacterial, fungal, parasitic, or viral infection which require therapy:
- Patients with acute bacterial infection requiring antibiotic use should delay screening/enrollment until the course of antibiotic therapy has been completed.
- Patients with known active hepatitis A, B, or C or who are known to be human immunodeficiency virus (HIV) positive
- Renal dialysis
- Non-SCD conditions or complications of SCD for which survival beyond 3 months is unlikely, in the opinion of the treating Investigator
- Any condition affecting drug absorption, such as major surgery involving the stomach or small intestine (prior cholecystectomy is acceptable)
- Participated in another clinical trial of an investigational agent (or medical device) within 30 days or 5 half-lives of date of informed consent, whichever is longer, or is currently participating in another trial of an investigational agent (or medical device)
- Medical, psychological, or behavioral conditions, which, in the opinion of the Investigator, may preclude safe participation, interfere with compliance or preclude informed consent
The Sponsor Medical Monitor makes the sole and final enrollment determination for any patient.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03943615
|Study Director:||Jonathan Sorof, MD||Global Blood Therapeutics, Inc.|
|Responsible Party:||Global Blood Therapeutics|
|Other Study ID Numbers:||
|First Posted:||May 9, 2019 Key Record Dates|
|Last Update Posted:||December 19, 2019|
|Last Verified:||December 2019|
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Genetic Diseases, Inborn